Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension - Pavel, Marianne Ellen; Cwikla, J.; Wolin, E.; Phan, A.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Capdevila, J.; Rindi, G.; Lombard-Bohas, C.; Liyanage, N.; Thanh, Truong X. -M; et al. (2018)
EVALuna2:35198